12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ABT-267: Additional Phase IIb data

Additional data from the open-label, international Phase IIb Aviator (Study M11-652) trial in 571 patients with HCV genotype 1 infection showed that 97.5% of treatment-naïve patients (n=79) and 93.3% of null responders (n=45) who received ABT-450 plus ritonavir, ABT-267, ABT-333 and ribavirin for 12 weeks achieved an SVR 12 weeks after the end of treatment. Additionally, 87.5% of treatment-naïve patients who received ABT-450 plus ritonavir, ABT-267, ABT-333 and ribavirin for 8 weeks achieved an SVR12 (n=80). In treatment-naïve patients, SVR12 rates for other 12-week ABT-450 regimens were 85.4% for ABT-450 plus ritonavir, ABT-333 and ribavirin (n=41); 89.9% for ABT-450 plus ritonavir, ABT-267 and ribavirin (n=79); and 87.3% for ABT-450 plus ritonavir, ABT-267 and ABT-333 (n=79). In null responders, ABT-450 plus ritonavir, ABT-267...

Read the full 607 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >